Data from the United Kingdom found that people more frequently reported temporary reactions like low fevers, fatigue, and pain as their immune system ramped up in the days following booster vaccination with Moderna's mRNA vaccine versus the one by Pfizer. And those boosted with Novavax's had fewer complaints than either of those. That finding was corroborated in an analysis of international data published last year.
Another group who waited on Novavax are biologists who geek out over its technology. When asked why he opted for Novavax, Florian Krammer, a virologist at the Icahn School
[
add
]
[
|
|
...
]